These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

555 related articles for article (PubMed ID: 24473129)

  • 1. Programmable removal of bacterial strains by use of genome-targeting CRISPR-Cas systems.
    Gomaa AA; Klumpe HE; Luo ML; Selle K; Barrangou R; Beisel CL
    mBio; 2014 Jan; 5(1):e00928-13. PubMed ID: 24473129
    [TBL] [Abstract][Full Text] [Related]  

  • 2. How CRISPR-Cas System Could Be Used to Combat Antimicrobial Resistance.
    Gholizadeh P; Köse Ş; Dao S; Ganbarov K; Tanomand A; Dal T; Aghazadeh M; Ghotaslou R; Ahangarzadeh Rezaee M; Yousefi B; Samadi Kafil H
    Infect Drug Resist; 2020; 13():1111-1121. PubMed ID: 32368102
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Survey of clustered regularly interspaced short palindromic repeats and their associated Cas proteins (CRISPR/Cas) systems in multiple sequenced strains of Klebsiella pneumoniae.
    Ostria-Hernández ML; Sánchez-Vallejo CJ; Ibarra JA; Castro-Escarpulli G
    BMC Res Notes; 2015 Aug; 8():332. PubMed ID: 26238567
    [TBL] [Abstract][Full Text] [Related]  

  • 4. An Attenuated CRISPR-Cas System in Enterococcus faecalis Permits DNA Acquisition.
    Hullahalli K; Rodrigues M; Nguyen UT; Palmer K
    mBio; 2018 May; 9(3):. PubMed ID: 29717009
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Using CRISPR-Cas systems as antimicrobials.
    Bikard D; Barrangou R
    Curr Opin Microbiol; 2017 Jun; 37():155-160. PubMed ID: 28888103
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cooperation between Different CRISPR-Cas Types Enables Adaptation in an RNA-Targeting System.
    Hoikkala V; Ravantti J; Díez-Villaseñor C; Tiirola M; Conrad RA; McBride MJ; Moineau S; Sundberg LR
    mBio; 2021 Mar; 12(2):. PubMed ID: 33785624
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CRISPR Content Correlates with the Pathogenic Potential of Escherichia coli.
    García-Gutiérrez E; Almendros C; Mojica FJ; Guzmán NM; García-Martínez J
    PLoS One; 2015; 10(7):e0131935. PubMed ID: 26136211
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Function of the CRISPR-Cas System of the Human Pathogen Clostridium difficile.
    Boudry P; Semenova E; Monot M; Datsenko KA; Lopatina A; Sekulovic O; Ospina-Bedoya M; Fortier LC; Severinov K; Dupuy B; Soutourina O
    mBio; 2015 Sep; 6(5):e01112-15. PubMed ID: 26330515
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The CRISPR-Cas Mechanism for Adaptive Immunity and Alternate Bacterial Functions Fuels Diverse Biotechnologies.
    Newsom S; Parameshwaran HP; Martin L; Rajan R
    Front Cell Infect Microbiol; 2020; 10():619763. PubMed ID: 33585286
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Presence of Type I-F CRISPR/Cas systems is associated with antimicrobial susceptibility in Escherichia coli.
    Aydin S; Personne Y; Newire E; Laverick R; Russell O; Roberts AP; Enne VI
    J Antimicrob Chemother; 2017 Aug; 72(8):2213-2218. PubMed ID: 28535195
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phage-delivered sensitisation with subsequent antibiotic treatment reveals sustained effect against antimicrobial resistant bacteria.
    Liu H; Li H; Liang Y; Du X; Yang C; Yang L; Xie J; Zhao R; Tong Y; Qiu S; Song H
    Theranostics; 2020; 10(14):6310-6321. PubMed ID: 32483454
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Genomic impact of CRISPR immunization against bacteriophages.
    Barrangou R; Coûté-Monvoisin AC; Stahl B; Chavichvily I; Damange F; Romero DA; Boyaval P; Fremaux C; Horvath P
    Biochem Soc Trans; 2013 Dec; 41(6):1383-91. PubMed ID: 24256225
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Functional Analysis of Porphyromonas gingivalis W83 CRISPR-Cas Systems.
    Burmistrz M; Dudek B; Staniec D; Rodriguez Martinez JI; Bochtler M; Potempa J; Pyrc K
    J Bacteriol; 2015 Aug; 197(16):2631-41. PubMed ID: 26013482
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Harnessing CRISPR-Cas systems for bacterial genome editing.
    Selle K; Barrangou R
    Trends Microbiol; 2015 Apr; 23(4):225-32. PubMed ID: 25698413
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Friendly Fire: Biological Functions and Consequences of Chromosomal Targeting by CRISPR-Cas Systems.
    Heussler GE; O'Toole GA
    J Bacteriol; 2016 May; 198(10):1481-6. PubMed ID: 26929301
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Endogenous Gene Regulation as a Predicted Main Function of Type I-E CRISPR/Cas System in
    Bozic B; Repac J; Djordjevic M
    Molecules; 2019 Feb; 24(4):. PubMed ID: 30795631
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Fluorescence-based methods for measuring target interference by CRISPR-Cas systems.
    Phan PT; Schelling M; Xue C; Sashital DG
    Methods Enzymol; 2019; 616():61-85. PubMed ID: 30691655
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The roles of CRISPR-Cas systems in adaptive immunity and beyond.
    Barrangou R
    Curr Opin Immunol; 2015 Feb; 32():36-41. PubMed ID: 25574773
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [CRISPR-Cas systems as weapons against pathogenic bacteria].
    Bikard D; Barrangou R
    Biol Aujourdhui; 2017; 211(4):265-270. PubMed ID: 29956653
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Covalent Modifications of the Bacteriophage Genome Confer a Degree of Resistance to Bacterial CRISPR Systems.
    Liu Y; Dai L; Dong J; Chen C; Zhu J; Rao VB; Tao P
    J Virol; 2020 Nov; 94(23):. PubMed ID: 32938767
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 28.